Featured
Allergy Research Group Acquires Metabolic Maintenance
We're excited to announce the acquisition of Metabolic Maintenance, a respected provider of premium supplements known for its commitment to science-based formulations. This strategic acquisition further solidifies ARG’s position in the market and significantly enhances its portfolio, particularly in the burgeoning stress and mood management categories.
Read now
Hypothyroidism and Depression: Why They’re So Often Confused
The overlap between hypothyroidism and depression is not a coincidence. It reflects shared physiology, shared neuroendocrine pathways, and a long history of clinical observation that continues to be supported by modern research. Understanding this overlap requires moving beyond symptom checklists and into the biology of how thyroid hormones interact with the brain.
Read now
Beyond the Uterus: Why Progesterone Still Matters After Hysterectomy
The idea that women without a uterus don’t need progesterone is misleading. While progesterone is no longer required to protect the endometrium after hysterectomy, it still plays important systemic roles throughout the body. Progesterone receptors exist in the brain, bones, breasts, blood vessels, and immune cells, meaning it can influence mood, anxiety, sleep quality, cognition, bone formation, breast comfort, inflammation, and metabolic and cardiovascular function. Data shows the therapeutic use of bioidentical progesterone in the right context, though it is not a cure-all and must be paired with healthy lifestyle choices.
Read now
The Perimenopause Puzzle: Why This Transition Can Be the Trickiest Time for Hormones
Perimenopause is a highly variable, hormonally dynamic transition leading up to menopause. Symptoms often shift month to month as progesterone declines and estrogen fluctuates unpredictably—making lab tests alone unreliable. Here we discuss how to recognize when a woman has entered the perimenopause or menopause stage of life, and then how to help alleviate their symptoms.
Read now
Estrogen: No Black Box Warning—Now What?
For more than two decades, fear stemming from early, oversimplified interpretations of the Women’s Health Initiative led many women and clinicians to avoid hormone replacement therapy, culminating in a black box warning on estrogen. In 2025, the FDA removed that warning for estrogen-only therapies, reflecting clearer evidence that risks depend heavily on age, timing, hormone type, and route of administration—not the universal danger once assumed. Updated research shows that starting hormone therapy within ten years of menopause, using bioidentical formulations, and choosing non-oral routes can significantly reduce risks, while estrogen-only therapy has not been shown to raise breast cancer risk. The label change does not mean hormone therapy is risk-free, but it does open the door to individualized, evidence-based decision-making. With better data and more nuance, women and clinicians can move forward with informed conversations rather than fear-driven avoidance.
Read now
Fighting Free Radicals with Antioxidants
Free radicals are natural byproducts of metabolism, but when unchecked, they can speed up aging and impact health. Antioxidants help neutralize these free radical threats and help maintain cellular balance.
Read now
The Hidden Risks of Unmetabolized Folic Acid (UMFA)
This is a discussion about how unmetabolized folic acid accumulates in the body, and the clinically documented risks associated with unmetabolized folic acid.
Read now
